Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

The INNODIA Type 1 Diabetes Natural History Study: a European cohort of newly diagnosed children, adolescents and adults.

Marcovecchio ML. et al, (2024), Diabetologia

Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells

Inaba A. et al, (2023), Nature Communications, 14

SARS-CoV-2 infection induces a long-lived pro-inflammatory transcriptional profile

Zhang J-Y. et al, (2023), Genome Medicine, 15

Gene expression signature predicts rate of type 1 diabetes progression.

Suomi T. et al, (2023), EBioMedicine, 92

Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes

Zhang J-Y. et al, (2022), Nature Communications, 13

Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration.

Carr ALJ. et al, (2022), Diabetes, 71, 1591 - 1596

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.

Dunger DB. et al, (2022), Trials, 23

Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

Jarvis LB. et al, (2021), Commun Biol, 4

Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes.

Robertson CC. et al, (2021), Nature genetics

Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus

Trzupek D. et al, (2021), Wellcome Open Research, 6, 149 - 149

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial

Marcovecchio ML. et al, (2020), Wellcome Open Research, 5, 49 - 49

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial

Marcovecchio L. et al, (2020)

Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic β-Cells.

Inshaw JRJ. et al, (2020), Diabetes care, 43, 169 - 177

Stochastic search and joint fine-mapping increases accuracy and identifies previously unreported associations in immune-mediated diseases

Asimit JL. et al, (2019), Nature Communications, 10

Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression

Ferreira RC. et al, (2019), Frontiers in Immunology, 10

Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice.

Mattner J. et al, (2019), PLoS genetics, 15

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

Peterson LB. et al, (2018), Journal of Autoimmunity, 95, 1 - 14

The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Oliveira JJ. et al, (2018), Arthritis Research & Therapy, 20

The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes

Seelig E. et al, (2018), JCI Insight, 3

A Novel Pkhd1 Mutation Interacts with the Nonobese Diabetic Genetic Background To Cause Autoimmune Cholangitis

Huang W. et al, (2018), The Journal of Immunology, 200, 147 - 162

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?